Researchers continue to excited about the medication , a novel dual agonist showing promising results in initial trials for size reduction . It acts by impacting both systems: GLP-1 and GIP, these, https://imogenshdz946040.alltdesign.com/a-new-prospect-for-body-loss-59510737